CoChat

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trial *

Yang, W., Chen, L., Ji, Q., Liu, X., Ma, J., Tandon, N., Bhattacharyya, A., Kumar, A., Kim, K.‐W., Yoon, K.‐H., Bech, O. M., Zychma, M. · 2011 · Diabetes, Obesity and Metabolism
Cited by 91

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Aim: To assess and compare the efficacy and safety of liraglutide with those of glimepiride, both in combination with metformin for the treatment of type 2 diabetes in Asian population from China, South Korea and India. Methods: A 16‐week, randomized, double‐blind, double‐dummy, four‐arm, active control trial was carried out. In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA 1c of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1). One subject withdrew immediately after randomization and before exposure. Results: HbA 1c was significantly reduced in all groups compared with baseline. Treatment with liraglutide 1.2 and 1.8 mg was non‐inferior to glimepiride (mean HbA 1c reduction: 1.36% points, 1.45% points and 1.39% points, respectively). No significant difference was shown in the percentage of subjects reaching American Diabetes Association HbA 1c target <7% or American Association of Clinical Endocrinologists target ≤6.5% between liraglutide 1.2 and 1.8 mg and glimepiride. Liraglutide was associated with a 1.8–2.4 kg mean weight reduction, compared with a 0.1 kg mean weight gain with glimepiride. Liraglutide led to a significantly greater reduction in systolic blood pressure (SBP) compared with glimepiride. Two subjects in the glimepiride group reported major hypoglycaemia while none in the liraglutide groups. Liraglutide was associated with about 10‐fold lower incidence of minor hypoglycaemia than glimepiride. Gastrointestinal disorders were the most common adverse events (AEs) for liraglutide, but were transient and resulted in few withdrawals. Conclusions: In Asian subjects with type 2 diabetes, once‐daily liraglutide led to improvement in glycaemic control similar to that with glimepiride but with less frequent major and minor hypoglycaemia. Liraglutide also induced a significant weight loss and reduced SBP and was generally well tolerated. The most frequently reported AE was transient nausea. The effect of liraglutide in this Asian population is comparable to the effects seen in Caucasian, African American and Hispanic populations in global liraglutide phase 3 trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2010.01323.x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 10

  1. 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  2. 10.1038/nrendo.2009.48 · DOI · Paper page
  3. McGill JB., 2009, Selecting among ADA/EASD tier 1 and tier 2 treatment options., J Fam Pract, 58, S26
  4. 10.1177/0145721707308407 · DOI · Paper page
  5. 10.1055/s-0029-1211750 · DOI · Paper page
  6. 10.1210/jc.2007-2109 · DOI · Paper page
  7. 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
  8. 2002, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects., J Postgrad Med, 48, 206
  9. 10.2337/dc06-9912 · DOI · Paper page
  10. 10.1210/10.1210/er.2006-0038 · DOI · Paper page

Cited by

See all 91

Metadata

Authors
Yang, W., Chen, L., Ji, Q., Liu, X., Ma, J., Tandon, N., Bhattacharyya, A., Kumar, A., Kim, K. ‐., Yoon, K. ‐., Bech, O. M., & Zychma, M.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2010-11-28
Volume
13
Issue
1
Pages
81-88
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1928513790
Cited by
91
References
13
FWCI
6.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trial *. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01323.x
The paper
Yang, W., Chen, L., Ji, Q., Liu, X., Ma, J., Tandon, N., Bhattacharyya, A., Kumar, A., Kim, K. ‐., Yoon, K. ‐., Bech, O. M., & Zychma, M. (2011). Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trial *. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01323.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.